Ketamine2021 virtual conference and  ASKP3  are proud to announce 

  • A series of free, short, 30-minute webinars held every two weeks
  • Held on 2nd and 4th Tuesdays at 12:30pm Eastern Time. (Usually 9:30am Pacific, 5:30pm GMT, 11:00pm Indian Standard)
  • Authors present for 15 minutes followed by 15 minutes Q&A. 
  • Questions are submitted through Zoom Q&A button. Discussion may evolve to also include interactive dialogue.
  • Recently published papers on ketamine and related compounds for the treatment of psychiatric disorders
  • A balance of RCTs, animal work, experimental medicine / human mechanism, case series
  • Recordings of presentations and Q&As will be made available through Ketamine Conference website to all registrants
  • Intended audience:  clinicians, clinical and pre-clinical scientists, industry, policy makers
  • Tuesday 10th November 2020 12.30pm EST; 5.30pm UK

    Ketamine normalizes subgenual cingulate cortex hyper-activity in depression. 
    Morris LS, Costi S, Tan A, Stern ER, Charney DS, Murrough JW. Neuropsychopharmacology (2020), 45(6):975-981.  PMID: 31896116
    Presenter: Laurel Morris, Assistant Professor, Icahn School of Medicine, Mount Sinai, New York 

    Tuesday 24th November 2020 12:30pm EST; 5.30pm UK

    Long-term outcome in outpatients with depression treated with acute and maintenance intravenous ketamine: A retrospective chart review. 
    Sakurai H, Jain F, Foster S, Pedrelli P, Mischoulon D, Fava M, Cusin C. J Affect Disord. 2020 Nov 1;276:660-666.
    PMID: 32871698
    Presenter: Cristina Cusin,  Assistant Professor of Psychiatry, Massachusetts General Hospital


    Tuesday 8th December 2020 12:30pm EST; 5.30pm UK

    The effectiveness of intravenous ketamine in adults with treatment-resistant major depressive disorder and bipolar disorder presenting with prominent anxiety: Results from the Canadian Rapid Treatment Center of Excellence. 
    McIntyre RS, Rodrigues NB, Lipsitz O, Nasri F, Gill H, Lui LM, Subramaniapillai M, Kratiuk K, Teopiz K, Ho R, Lee Y, Mansur RB, Rosenblat JD.  J Psychopharmacol. 2020 Oct 11 Epub ahead of print. 
    PMID: 33040665
    Presenter: Roger McIntyre,  Professor of Psychiatry and Pharmacology, University of Toronto

    Tuesday 22nd December 2020 12:30pm EST; 5.30pm UK

    Sex-specific neurobiological actions of prophylactic (R,S)-ketamine, (2R,6R)-hydroxynorketamine, and (2S,6S)-hydroxynorketamine. 
    Chen BK, Luna VM, LaGamma CT, Xu X, Deng SX, Suckow RF, Cooper TB, Shah A, Brachman RA, Mendez-David I, David DJ, Gardier AM, Landry DW, Denny CA.  Neuropsychopharmacology. 2020 Aug;45(9):1545-1556. 
    PMID: 32417852
    Presenter: Christine DennyAssistant Professor of Clinical Neurobiology (in Psychiatry), Columbia University, New York

    About Ketamine International Journal Club

    • Independent of industry funding
    • Programmed and run by academic clinicians at Oxford and psychiatric trainees. Organisational support from the American Society of Ketamine Physicians, Psychotherapists & Practitioners
    • Complements Ketamine2021 virtual conference (25-26th March, 2021) and ASKP3 conference (October/November, 2021)
    • E-mail enquiries to:
    Rupert McShane, Associate Professor, Department of Psychiatry, University of Oxford, UK
    Sara Costi, Wellcome Trust Doctoral Training Fellow, Harmer Group, Department of Psychiatry, University of Oxford, UK
    Jacek Lindner, Psychiatric Trainee, Gartnavel Royal Hospital, NHS Greater Glasgow & Clyde, UK

    Journal club enquiries or unsubscribe